Inhibiting tumor growth and metastasis in highly aggressive breast cancers with centrosome amplification
通过中心体扩增抑制高度侵袭性乳腺癌的肿瘤生长和转移
基本信息
- 批准号:10670436
- 负责人:
- 金额:$ 33.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:4T1AcetylationApoptosisApoptoticBCL2 geneBinding ProteinsBiological AssayBreastBreast Cancer ModelBreast Cancer PatientCDC2 geneCRISPR/Cas technologyCell DeathCell Death InductionCell LineCell PolarityCell divisionCellsCentrosomeClathrinClinicClustered Regularly Interspaced Short Palindromic RepeatsDataDefectDistant MetastasisExperimental ModelsExtracellular MatrixFocal AdhesionsGeneticGoalsGolgi ApparatusGrowthHDAC2 geneHigh PrevalenceImmunocompetentImmunofluorescence ImmunologicIn VitroIntegrinsInterphaseInterphase CellInvadedKnock-outLegal patentLungMalignant NeoplasmsMammary NeoplasmsMass Spectrum AnalysisMediatingMethodsMicrotubulesMissionMitosisMitoticMitotic spindleModelingMolecularMouse Mammary Tumor VirusMutationNeoplasm MetastasisNoninfiltrating Intraductal CarcinomaNormal CellOrganoidsOutputOvarianPatient-Focused OutcomesPhenotypePhysiologicalPrimary NeoplasmPrognosisProstateProteinsPublic HealthResearchRoleTP53 geneTestingTherapeuticToxic effectTransgenic MiceTubulinTumor-DerivedUnited States National Institutes of HealthXenograft procedureadvanced breast canceraggressive breast cancercancer cellcell motilityclinically relevantdisabilityhigh riskimprovedin vivoinhibitorinnovationlive cell imagingmalignant breast neoplasmmigrationmortalitymouse modelmutantnoveloverexpressionpatient derived xenograft modelpatient subsetspolarized cellpolyoma middle tumor antigenpre-clinicalpreventsuccesstherapeutic targetthree dimensional cell culturetraffickingtriple-negative invasive breast carcinomatumortumor growthtumor progression
项目摘要
PROJECT SUMMARY
Centrosome amplification (CA) is highly prevalent in cancer and strongly associated with tumor progression
and worse prognosis in several different cancers, including breast, prostate, ovarian and lung. Centrosome
amplified cells also demonstrate increased motility and invasiveness leading to metastasis. Moreover, CA is
associated with genetic aberrations, such as p53 mutation that are commonly observed in aggressive forms
of cancers, such as the triple negative breast cancer (TNBC). Our long-term goal is to target the growth and
metastatic dissemination of aggressive breast tumors with CA that will ultimately lead to improved patient
outcome. The overall objectives of this project are to (i) inhibit tumor growth in breast cancer models with CA
via inducing centrosome de-clustering and formation of multipolar spindles upon targeting transforming acidic
coiled-coil 3 (TACC3), and to (ii) block local invasion and metastatic dissemination in CA models by
preventing cell polarization, migration and invasion upon inhibition of TACC3. The central hypothesis is that
TACC3 inhibition will, on one hand, prevent active clustering of amplified centrosomes into two spindle poles
during mitotic cell division leading to multipolar mitosis and apoptotic cell death in p53 altered cells, and on
the other hand disrupts centrosome and Golgi re-orientation, microtubule nucleation and cell polarization in
interphase cells leading to decreased migration. The rationale for this project is that TACC3 inhibition
represents a unique opportunity to eliminate the most aggressive tumors that have supernumerary
centrosomes, while sparing the normal cells. The central hypothesis will be tested by pursing two specific
aims: 1.) To inhibit tumor growth in aggressive breast cancer models with CA by targeting TACC3, and 2.)
To prevent metastasis in aggressive breast cancer models with CA by targeting TACC3. State-of-the-art
experimental settings with translatable approaches will be employed, including tumor organoids, patient-
derived xenografts and immunocompetent transgenic mouse model of advanced breast cancer that we
characterized in terms of CA. The research proposed in this project is innovative as it aims to study
mitosis/interphase-specific interactomes of TACC3 that are essential for TACC3-mediated cell division in
mitotic cells and cell polarity in interphase cells that we propose to block using our novel and highly potent
TACC3 inhibitor as well as using CRISPR-mediated knock-out. The proposed project is significant because
it is expected to provide key mechanistic and phenotypic pre-clinical data to support the notion that targeting
TACC3 concomitantly inhibits tumor growth and metastasis in breast cancer models with CA, which will then
dramatically reduce mortality rates among patient subpopulation with highly aggressive cancers.
项目总结
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ozgur Sahin其他文献
Ozgur Sahin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ozgur Sahin', 18)}}的其他基金
Developing novel LOX inhibitors to target chemotherapy resistant TNBC
开发新型 LOX 抑制剂以靶向化疗耐药的 TNBC
- 批准号:
10696810 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
Inhibiting tumor growth and metastasis in highly aggressive breast cancers with centrosome amplification
通过中心体扩增抑制高度侵袭性乳腺癌的肿瘤生长和转移
- 批准号:
10621529 - 财政年份:2022
- 资助金额:
$ 33.2万 - 项目类别:
Nanomechanical studies of cells and biomolecules
细胞和生物分子的纳米力学研究
- 批准号:
10406574 - 财政年份:2022
- 资助金额:
$ 33.2万 - 项目类别:
Nanomechanical studies of cells and biomolecules
细胞和生物分子的纳米力学研究
- 批准号:
10668957 - 财政年份:2022
- 资助金额:
$ 33.2万 - 项目类别:
Overcoming chemoresistance in triple negative breast cancer
克服三阴性乳腺癌的化疗耐药性
- 批准号:
10345694 - 财政年份:2021
- 资助金额:
$ 33.2万 - 项目类别:
Inhibiting tumor growth and metastasis in highly aggressive breast cancers with centrosome amplification
通过中心体扩增抑制高度侵袭性乳腺癌的肿瘤生长和转移
- 批准号:
10298311 - 财政年份:2021
- 资助金额:
$ 33.2万 - 项目类别:
Overcoming chemoresistance in triple negative breast cancer
克服三阴性乳腺癌的化疗耐药性
- 批准号:
10541879 - 财政年份:2021
- 资助金额:
$ 33.2万 - 项目类别:
Overcoming chemoresistance in triple negative breast cancer
克服三阴性乳腺癌的化疗耐药性
- 批准号:
10642470 - 财政年份:2021
- 资助金额:
$ 33.2万 - 项目类别:
Nanomechanical imaging of protein dynamics via programmable DNA interactions
通过可编程 DNA 相互作用进行蛋白质动力学纳米力学成像
- 批准号:
10020421 - 财政年份:2019
- 资助金额:
$ 33.2万 - 项目类别:
Nanomechanical imaging of protein dynamics via programmable DNA interactions
通过可编程 DNA 相互作用进行蛋白质动力学纳米力学成像
- 批准号:
10217200 - 财政年份:2019
- 资助金额:
$ 33.2万 - 项目类别:
相似海外基金
Investigating the functions of histone acetylation in genome organization and leukemogenesis
研究组蛋白乙酰化在基因组组织和白血病发生中的功能
- 批准号:
EP/Y000331/1 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
Research Grant
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
- 批准号:
10677295 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
PDK2 在心力衰竭中的新作用:通过代谢调节和组蛋白乙酰化调节线粒体核串扰
- 批准号:
10635599 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
Regulation of hepatic lysine N-acetylation by cysteine proximity due to alcohol toxicity
酒精毒性导致的半胱氨酸接近对肝脏赖氨酸 N-乙酰化的调节
- 批准号:
10752320 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
Histone Acetylation Regulates Microglial Innate Immune Memory
组蛋白乙酰化调节小胶质细胞先天免疫记忆
- 批准号:
478927 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
Operating Grants
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
- 批准号:
10855703 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
Obesity-related hypertension: the contribution of PPAR gamma acetylation and asprosin
肥胖相关高血压:PPAR γ 乙酰化和白脂素的贡献
- 批准号:
10654210 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
- 批准号:
10733915 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
In vivo tracing of hepatic ethanol metabolism to histone acetylation: role of ACSS2 in alcohol-induced liver injury
肝脏乙醇代谢与组蛋白乙酰化的体内追踪:ACSS2 在酒精性肝损伤中的作用
- 批准号:
10667952 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:
The function of TWIST1 acetylation in cell fate and tissue development
TWIST1 乙酰化在细胞命运和组织发育中的作用
- 批准号:
10726986 - 财政年份:2023
- 资助金额:
$ 33.2万 - 项目类别:














{{item.name}}会员




